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ABSTRACT
Background The aim of the study was to better
characterise the immunological origin and the behaviour
of interleukin (IL)-23-responsive innate lymphoid cells
(ILCs) in the gut, synovial ﬂuid (SF) and bone marrow
(BM) of patients with ankylosing spondylitis (AS).
Methods ILC1, ILC2 and ILC3 cells were determined
and characterised by confocal microscopy and ﬂow
cytometry in ileal and BM biopsies, in peripheral blood
(PB) and SF mononuclear cells obtained from patients
with AS and controls. Mucosal vascular addressin cell
adhesion molecule 1 (MADCAM-1), IL-7, IL-15 and
aggregates of lymphoid tissue inducer cells (LTi) were
evaluated by immunohistochemistry. The in vitro ability
of epithelial cells in driving the differentiation of ILC3
and the effect of tumour necrosis factor inhibitors (TNFi)
on the frequency of ILC3 and the expression of
MADCAM1 were also assessed.
Results ILC3 characterised as Lyn−RORc−Tbet+
NKp44+ cells were signiﬁcantly expanded in the gut, SF
and BM of patients with AS compared with controls,
produced high levels of IL-17 and IL-22 and expressed
α4β7. MADcAM1 was overexpressed in BM and ileal
high endothelial venules. IL-7 was signiﬁcantly increased
in AS gut, especially in the context of Paneth cells, and
accompanied by the presence of aggregates of c-kit/IL-
7R+ cells (LTi). In in vitro experiments, epithelial cells
from patients with AS actively induced differentiation of
ILC3 from LTi. TNFi efﬁcacy was accompanied by a
signiﬁcant decrease in the percentage of intestinal and
circulating ILC3 and in the expression of MADCAM1.
Conclusions Gut-derived IL-17+ and IL-22+ILC3 are
expanded in the peripheral blood, SF and inﬂamed BM
of patients with AS, suggesting the presence of an active
homing axis between the gut and the inﬂamed sacroiliac
joints.
INTRODUCTION
Interleukin (IL)-23 is considered to be a central
cytokine in ankylosing spondylitis (AS).1 2 The
intestine appears to be the main site of IL-23 pro-
duction,2 3 and there is emerging clinical evidence
that blocking IL-23 in AS may be effective.4
IL-23-sensitive entheseal resident T cells
(IL-23R+RAR-related orphan receptor γt (ROR-γt)
(+)CD3(+)CD4(−)CD8(−), stem cell antigen 1
(Sca1)(+) cells) have been observed in a murine
model of AS.5 These cells have been found to
release IL-17 and IL-22, cytokines considered
important actors in driving spinal inﬂammation
and osteoproliferation.5 Although well charac-
terised from a phenotypic point of view, these cells
have not been demonstrated in humans, and the
exact nature of these cells and their developmental
origin in patients with AS remain elusive.
Interestingly, these cells share several immuno-
logical similarities with speciﬁc subsets of innate
lymphoid cells (ILCs).
ILCs populations are specialised cells involved in
the regulation of innate immunity and inﬂamma-
tion through the secretion of polarised cytokines
and chemokines.6 Based on the cytokine properties,
ILCs are classiﬁed into three groups (ILC1, ILC2
and ILC3): ILC1 express the transcription factor
T-bet, produce interferon-γ (IFN-γ) and mediate
immunity against intracellular pathogens and
tumors7; ILC2 mainly produce IL-5 and IL-13;
ILC3s are an important source of ‘type 17’ cyto-
kines, IL-22 and IL-17, in response to IL-23,
express the retinoic acid-ROR-γ and are required
for mediating immunity to extracellular bacterial
infections,8 also providing help to marginal zone B
cells,9 and may also play a proinﬂammatory role.10
ILC3 seem to be essentially mucosal-restricted cells,
developmentally related to lymphoid tissue-induced
cells (LTi) and dependent on IL-7 for their differen-
tiation.11 12 These ROR-γ+ cells are essentially
involved in protective response by negatively regu-
lating Th17 cells through the modulation of intes-
tinal microﬂora.13 14 Speciﬁcally in the gut of
patients with AS, ILC3 expressing the natural cyto-
toxicity receptor NKp44 are signiﬁcantly expanded,
produce IL-22 and induce mucins production and
goblet cells hyperplasia.15 Although the ligand for
NKp44 in normal tissues has not yet been identi-
ﬁed, it seems to bind to an unusual isoform of the
mixed lineage leukaemia-5 protein.16 The contin-
ued engagement of NKp44 and cytokine receptors,
however, seems to induce a potent proinﬂamma-
tory programme in NKp44+ILC3 cells.10
Since the prevalent expression of IL-23 in the
gut of patients with AS2 and the strong expansion
of NKp44+ILC3s we previously demonstrated,15 in
this study we aimed to better characterise ILC3 and
to study ILC1 and ILC2 in the gut of AS. In
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consideration of the role of the α4β7 integrin in promoting
homing of immune cells to intestinal site,17 the aim of this study
was also to verify whether gut-derived ILCs may express the
α4β7 integrin and recirculate in the peripheral blood, inﬂamed
bone marrow (BM) and synovial ﬂuid of patients with human
leucocyte antigen (HLA)-B27 AS.
METHODS
Patients
Thirty consecutive patients with HLA-B27affected by AS diag-
nosed according to the New York classiﬁcation criteria18 were
considered for this study. All the patients had to have active
disease deﬁned as a Bath ankylosing spondylitis disease activity
index (BASDAI)19–20 of 4 or more and a positive MRI scan of
sacroiliac (SI) joints. Multiple adjacent ileal mucosal biopsies
were obtained from all the patients with AS. Fifteen healthy sub-
jects, undergoing ileocolonoscopy for diagnostic purposes but
without evidence of underlying disease, were also consecutively
enrolled and considered as controls (baseline characteristics of
patients and controls are speciﬁed in online supplementary table
S1). Peripheral blood mononuclear cells (PBMCs) were obtained
from all the patients and controls. Synovial ﬂuid was obtained
from 4 out of the 30 patients with AS and from additional 5
patients with osteoarthritis. Additional ﬁve patients with
HLA-B27+, with nrAxSpA and SI joints involvement as demon-
strated by MRI were considered for this study. These patients
displayed hypergammaglobulinemia (<3 g/dL) and were
referred by haematologist to undergo BM biopsy after informed
consent, suspecting gammopathy of undetermined signiﬁcance
(MGUS) for diagnostic purpose. BM samples obtained from ﬁve
patients with hypergammaglobulinemia, without any history of
inﬂammatory joint disease, undergoing BM biopsy for diagnos-
tic purpose were considered as controls. Plasma cells were
<10% in all the patients and displayed a normal phenotype
(CD38+CD56−CD19+). Finally, peripheral blood and gut
samples were obtained from ﬁve out of the 30 patients with AS
after anti-tumour necrosis factor (TNF)α therapy (three adali-
mumab and two inﬂiximab, mean duration of treatment 16
±6 months).
Histomorphological grading and immunohistochemistry
Gut specimens from patients with AS were divided according to
the histological results as previously described21 into three
groups: normal gut histology (n=10), acute (n=8) and chronic
(n=12) inﬂammation. Immunohistochemistry was performed as
previously described3 on ileal samples obtained from patients
with AS and controls and tonsils (considered as positive con-
trols). A list of primary and secondary antibodies used is
Figure 1 Innate lymphoid cells type 3 in the gut of patients with ankylosing spondylitis (AS). (A–D, F, H–K) Representative dot plots showing the
gating strategy for innate lymphoid cell (ILC)3 in the gut of patients with AS. (E) Percentage of ILC3 in the ileum of AS patients without intestinal
inﬂammation, acute and chronic inﬂammation and normal controls (NCs). (F) Representative dot plot showing α4β7 expression on ileal ILC3 of AS
patients. (G and H) Representative dot plots showing the expression of interleukin (IL)-23R (G) of RORc (H) and Tbet (I) in ileal ILC3. (J) Percentages
of RORc+ and Tbet+ ILC3 in the gut of patients with AS. (K) Representative dot plot showing the cytokine production by intestinal ILC3 of patients
with AS. (L) Percentage IL-17 and IL-22 expressing cells among intestinal ILC3. Data are expressed as individual data points (mean). p<0.0001.
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provided in online supplementary table S2. The number of posi-
tive cells was determined by counting positively stained cells on
photomicrographs obtained from three random high-power
microscopic ﬁelds (400× magniﬁcation) under a Leica DM2000
optical microscope, using a Leica DFC320 digital camera (Leica,
Rijswijk, the Netherlands). To speciﬁcally address the presence
of cryptopatches and ILCs, triple stainings were performed on
parafﬁn-embedded sections of human ileum and the sections
were treated with FITC-, Rhodamine Red or Cy-5-conjugated
antimouse or antirabbit antibodies (Invitrogen), plus RNasi
(200 ng/mL) and counterstained using Toto-3 iodide (642/660;
Invitrogen) or 40,6-diamidino-2-phenylindole (DAPI) (Life
Technologies). Confocal analysis was used to acquire ﬂuores-
cence staining.
RNA extraction and quantitative TaqMan real-time PCR
(RT-PCR) for ileal biopsies
Total RNA was extracted using the Qiagen RNeasy Mini kit,
with on-column DNase I digestion. A total of 1 μg of RNA was
reverse-transcribed to complementary DNA (cDNA) using a
ThermoScript First-Strand cDNA Synthesis kit (Invitrogen). For
quantitative TaqMan real-time PCR, sets of primers and probes
were obtained from Applied Biosystems (see online supplemen-
tary table S2). Samples were run in triplicate using the Step-One
Real-Time PCR system (Applied Biosystems). Relative changes in
gene expression between controls and patients were determined
using the ΔΔCt method as previously described. Final values
were expressed as fold of induction.
Flow cytometry analysis of surface and intracellular
antigens
Lamina propria mononuclear cells (LPMCs), PBMCs, synovial
mononuclear cells and BM mononuclear cells were respectively
isolated from the gut, the peripheral blood, synovial ﬂuid and
BM of patients with AS and healthy controls as previously
described.3 For detection of intracellular cytokine production,
cells were stimulated with phorbol myristate acetate (60 ng/mL)
and inomycin (1 μg/mL) as previously described.22 A list of the
antibodies used is provided in online supplemental table S2.
Flow cytometric analysis was performed using a FACSCanto
and FACScalibur (Becton Dickinson), and cell death was
assessed by trypan blue exclusion. At least 50 000 cells (events)
Figure 2 Cryptopatches are present and Paneth cells produce interleukin (IL)-7 in the gut of patients with ankylosing spondylitis (AS). (A and B)
Representative images showing a cluster of c-kit-stained cells in the gut of a patient with AS (arrow) (A) but not in control (B). (C–F) Cryptopatches
in the gut of patients with AS. Representative images of confocal analysis of Thy-1, C-kit and CD3 co-localisation in gut tissues of patients with AS.
(C) Single staining for Thy-1; (D) single staining for c-kit; (E) single staining for CD3. Nuclei were counterstained with 40,6-diamidino-2-phenylindole
(DAPI) (insert). (F) Merged triple staining of Thy-1, c-Kit and CD3. Cryptopatches were deﬁned as aggregates of c-kit+Thy-1+CD3− cells. (G and H)
RT-PCR for IL-7 and IL-15 in the gut of patients with AS and normal controls (NCs); *p<0.05. (I and J) Representative microphotographs showing
IL-7 and IL-15 staining in the gut of patients with AS. IL-7 (I) but not IL-15 ( J) was signiﬁcantly upregulated at the bottom of intestinal crypts.
(K–M) Representative images of confocal analysis of IL-7 and α-defensin5 co-localisation in gut tissues of patients with AS. (K) Single staining for
IL-7; (L) single staining for α-defensin5; (M) merged double staining of IL-7 and α-defensin5. (A, C–F and K–M) Original magniﬁcation ×250.
(B) Original magniﬁcation ×100. (I and J) Original magniﬁcation ×630. Data are expressed as individual data point (mean). *p<0.0001.
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were acquired for each sample. LPMCs were expressed as per-
centage of cells within the lymphocyte gate. The acquired data
were analysed using the CellQuest and FlowJo software
programs.
Cell cultures
In order to evaluate the role of epithelial cells in regulating the
differentiation of ILCs type 3, epithelial cell fraction was iso-
lated from LPMC as described by Van Damme et al.23 CD117+
lin− precursor-enriched mononuclear cells were isolated from
tonsils obtained from normal donors using lineage-marker
(negative depletion with antibodies to CD5, CD45R (B220),
CD11b, Gr-1 (Ly-6G/C), 7-4 and Ter-119) and c-kit microbeads
(positive selection) and magnetic-activated cell sorting techni-
ques (Miltenyi Biotech GmbH, Bergisch Gladbach, Germany)
according to the manufacturer’s instructions. Isolated
CD117+lin- were then cultured with intestinal epithelial cell
fraction (1:1), and the percentage of ILC3 was assessed by ﬂow
cytometry. All cultures were set up in triplicate and cells were
used for ﬂow cytometric analyses.
Statistical analysis
Student’s t test or the non-parametric Mann–Whitney test was
used to calculate the statistical signiﬁcance between groups.
Spearman’s rank correlation was performed to correlate the
number of ILC3 with the disease activity assessed by BASDAI in
AS. p Values <0.05 were considered signiﬁcant.
RESULTS
ILC3, but not ILC1 and ILC2, is expanded in the gut of AS
and is developmentally related to LTi cells
ILC populations were assessed by ﬂow cytometry and confocal
microscopy analysis. As shown in online supplementary ﬁgure
S1, no signiﬁcant expansion of ILC1 (see online supplementary
ﬁgure S1A–E, K, L) and/or ILC2 (see online supplementary
ﬁgure S1F–J, M, N) was observed in the gut of patients with
AS, independently by the level of inﬂammation, as compared to
controls. Conversely, by confocal analysis we demonstrated a
consistent expansion of NKp44+ILC3 in patients with AS with
acute and chronic gut inﬂammation (see online supplementary
ﬁgure S2A–E) signiﬁcantly correlated with the disease activity as
assessed by the BASDAI (r2=0.69, p<0.001) (see online supple-
mentary ﬁgure S2F).24 The expansion of ILC3 was conﬁrmed
by ﬂow cytometry (ﬁgure 1A–E and online supplementary
ﬁgure S3). These cells were characterised by the expression of
the natural cytotoxic receptor (NCR) NKp44 (ﬁgure 1D), were
negative for CD4, CD8, CD56, CD14, CD19, TCRγδ and
iNKT (Lyn−) (ﬁgure 1B) and express the IL-23R (ﬁgure 1G).
Immunologically, ILC3 cells produced IL-17 and IL-22, a small
percentage of cells co-expressing both cytokines (ﬁgure 1K, L).
Despite ILC3 having been described to express the transcription
factor RORc, in patients with AS these cells were almost totally
Tbet+ (ﬁgure 1H–J). ILC3 have been developmentally related
to LTi cells, this process requiring the IL-7 signalling.12 In this
regard, we ﬁrst evaluated the tissue distribution of LTi cells in
the gut of patients with AS and controls. As shown in ﬁgure 2,
Figure 3 Epithelial cells from ankylosing spondylitis (AS) drive innate lymphoid cell (ILC)3 differentiation from lymphoid tissue inducer (LTi) cells.
LTi cells were isolated from tonsils of normal donors and co-cultured with epithelial cells isolated for the gut of patients with AS. After co-culture
expansion of ILC3 was observed (A–E) with a different modulation of cytokine production (F). Data are expressed as individual data points (mean)
or as mean (SD).
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aggregates of c-kit+ (a marker of LTi cells) cells were observed
at the bottom of intestinal crypts in the gut of patients with AS
(ﬁgure 2A) but not of controls (ﬁgure 2B). Clusters of
CD3−c-kit+Thy1+ cells were conﬁrmed in the gut of patients
with AS (ﬁgure 2C–F) in close proximity of intestinal crypts
indicating with high probability the presence of cryptopatches
in AS. Since the important role of IL-7 and IL-15 in modulating
the fate of ILCs, we next evaluated their expression at both
m-RNA and protein levels. IL-7 and IL-15 were both signiﬁ-
cantly overexpressed at m-RNA level compared with controls
(ﬁgure 2G, H). Analysis of tissue expression and distribution of
IL-7 (ﬁgure 2I) and IL-15 (ﬁgure 2J) in the gut of patients with
AS showed intense staining only for IL-7 in AS and in particular
in the context of epithelial cells located at the bottom of intes-
tinal crypts highly resembling Paneth cells (PC) (ﬁgure 2I).
IL-7-producing cells in the gut of patients with AS were
conﬁrmed to be PC since their co-expression of α-defensin5, a
speciﬁc marker for PC (ﬁgure 2K–M). Since PC in the gut of AS
produce IL-23p192 and IL-7, thus potentially participating in
the differentiation and expansion of ILCs, we next tried to
evaluate whether epithelial cells may drive ILC3 differentiation.
Epithelial cell fraction isolated from intestinal biopsies of
patients with AS and controls, as previously described,23 was
co-cultured with isolated LTi cells obtained from tonsils of
normal donors. Co-culture of LTi cells with epithelial cells of
AS, but not controls (data not shown), resulted in the expansion
of ILC3s (ﬁgure 3A–E) producing equal amount of IL-17 and
IL-22 (ﬁgure 3F), indicating a prominent role of epithelium in
driving ILC3s expansion.
ILC3s are expanded in the peripheral blood, synovial ﬂuid
and BM of patients with AS and express α4β7 integrin
We next evaluated the frequency of ILC3 in the peripheral
blood, synovial ﬂuid and BM of patients with AS. We observed
a signiﬁcant expansion of ILC3 cells in the peripheral blood
(ﬁgure 4A–E), synovial ﬂuid (see online supplementary ﬁgure
S4A) and BM blood (5A–E) of patients with AS compared with
controls. These cells displayed different cytokine production in
the different compartments. In the peripheral blood, ILC3
prevalently produced IL-22, being the production of IL-17
alone or of IL-22/IL17 conﬁned to a small subset of these cells
(ﬁgure 4K, L). Among synovial ﬂuid and BM mononuclear cells
ILC3 produced exclusively IL-22 (ﬁgure 5K, L and see online
supplementary ﬁgure S4B).
In order to evaluate whether ILC3 present in the peripheral
blood and in the different sites of inﬂammation of patients with
AS were from gut origin, we evaluated the expression of α4β7
integrin on their surface. Among peripheral blood and BM
Figure 4 Innate lymphoid cells type 3 in the peripheral blood of patients with ankylosing spondylitis (AS). (A–D, F, H–K) Representative dot plots
showing the gating strategy for innate lymphoid cell (ILC)3 in the peripheral blood of patients with AS. (E) Percentage of ILC3 in the peripheral
blood of patients with AS and normal controls (NCs). (F) Representative dot plot showing α4β7 expression on circulating ILC3 of patients with AS.
(G) Percentage of α4β7+ cells among circulating ILC3 of patients and controls. (H–J) Representative dot plots showing the expression of interleukin
(IL)-23R on ILC3 (H), of RORc (I) and T-bet ( J). (K) Representative dot plot showing the cytokine production by circulating ILC3. (L) Percentage of
IL-17-expressing and IL-22-expressing cells among circulating ILC3. Data are expressed as individual data points (mean).
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ILC3, a signiﬁcantly higher percentage of ILC3 displayed α4β7
positivity compared with controls (ﬁgures 4F, G and 5F, G).
Since the speciﬁc counter-receptor of α4β7 is the addressin
mucosal vascular addressin cell adhesion molecule 1
(MAdCAM1),25 we next evaluated the expression of
MAdCAM1 in the gut and in the BM. As shown in ﬁgure 6, a
signiﬁcant upregulation of MAdCAM1 was observed in the gut
(ﬁgure 6A–C) and in the BM (ﬁgure 6H–J) of patients with AS
compared with controls. In particular, MAdCAM1 immune-
reactivity was observed exclusively in high endothelial venules
(HEVs) in BM and in close proximity to intestinal crypts in the
gut (ﬁgure 6A). To conﬁrm the HEV expression of MAdCAM1,
gut and BM sections of patients with AS were stained for
MAdCAM1 and PNAd, a speciﬁc marker for HEV, showing that
HEV express MAdCAM1 in AS ileum (ﬁgure 6D–G) and BM
(ﬁgure 6K–N). Altogether these ﬁndings should indicate a gut
origin for circulating and tissue ILC3 in AS.
TNF-blocking agents reduce the percentage of circulating
and gut ILC3 and the expression of MAdCAM in the gut of
patients with AS
TNF-blocking agents have been demonstrated to reduce the
inﬂammation in patients with AS and to modulate several
immunological functions.26 The demonstration of an effect of
TNF-blocking agents on ILC, if any, is however lacking. Five
patients with AS treated with TNF-blocking agents were reas-
sessed for the frequency of circulating and intestinal ILC3 and
for the gut expression of MAdCAM-1. As shown in online sup-
plementary ﬁgure S5, anti-TNF therapy results in a signiﬁcant
clinical amelioration, a signiﬁcant reduction of ILC3 at both sys-
temic (see online supplementary ﬁgure S5A–C) and gut level
(see online supplemental ﬁgure S5D–F) and a strong reduced
expression of MAdCAM1 in ileal samples (see online supple-
mentary ﬁgure S5G), indicating a role this therapeutic strategy
plays in modulating also the innate immune responses in
patients with AS.
DISCUSSION
In this study, we provide the ﬁrst evidence that a unique innate
immunological signature characterises the gut of patients with
AS and suggests that gut cell migration of ILC3 might be
involved in the development of AS. Type 3 ILC, which we
deﬁned as Lyn−IL-23R+NKp44+Tbet+RORc− cells, were found
to be expanded in the gut but also in the peripheral blood, in
the synovial ﬂuid and in the BM of patients with AS and
express the homing integrin α4β7. In addition, MAdCAM1, the
α4β7 ligand, was found to be highly represented in the gut and
in the inﬂamed BM of AS, suggesting that a recirculation of
Figure 5 Innate lymphoid cells type 3 in the bone marrow (BM) of patients with ankylosing spondylitis (AS). (A–D, F, H–K) Representative dot
plots showing the gating strategy for innate lymphoid cell (ILC)3 in the BM of patients with AS. (E) Percentage of ILC3 in the peripheral blood of
patients with AS and normal controls (NCs). (F) Representative dot plot showing α4β7 expression on circulating ILC3 of patients with AS. (G)
Percentages of α4β7+ in the BM of patients and controls. (H–J) Representative dot plots showing the expression of interleukin (IL)-23R on ILC3 (H),
of RORc (I) and T-bet ( J) on BM ILC3. (K) Representative dot plot showing the cytokine production by circulating ILC3. (L) Percentage
IL-17-expressing and IL-22-expressing cells among BM ILC3. Data are expressed as individual data points (mean).
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ILC3 between the gut and the BM occurs. In particular, ILC3
were predominantly expanded in the more inﬂamed gut of AS
compared with the acute and chronic inﬂamed intestine of
patients with AS, and produced both IL-17 and IL-22. Finally,
in the anti-TNF-treated patients, we observed a signiﬁcant
reduction of intestinal and circulating ILC3 and of the gut
MADCAM1 expression. Altogether these results suggest a role
for IL-23-sensitised gut-resident ILC3 migration in the develop-
ment of AS.
ILCs are different populations of cells with lymphoid
characteristics but without rearrangement of antigen receptors,
mainly distinguished into three groups: IFN-γ-producing ILC1
cells, T helper type 2 cytokines producing ILC2 cells, and IL-17
and IL-22 producing ILC3 cells that are associated with the
gastrointestinal mucosa.9 27–29 Differently from the ‘classic’
group, the ILC3 we found in AS were characterised by the high
expression of IL-17 and IL-22 and of the transcription factor
T-bet. The high percentage of IL-17+ILC3 cells we observed
was unexpected compared with murine studies and may suggest
a predominant innate source of IL-17 in AS gut. Finally, the
absence of RORc in AS intestinal ILC3 could be related to a
speciﬁc stage of differentiation of these cells since it has been
demonstrated that ILC3s may follow a differentiation pro-
gramme in which they ﬁrst upregulate T-bet, then acquire NCRs
and then downregulate RORγt, allowing for phenotypic and
functional plasticity.30–32
The mammalian gastrointestinal tract contains a well-
organised immune system consisting of the gut-associated
lymphoid tissues that includes the Peyer’s patches and the iso-
lated lymphoid follicles (ILFs). Subclinical gut inﬂammation of
patients with AS has been demonstrated to be characterised by a
signiﬁcant increased number of lamina propria ILF.33 In mice,
ILF formation is induced postnatally by commensal microbiota
and requires the formation of cryptopatches, structures contain-
ing LTi cells (a distinct population of group 3 ILCs).6 34 35
During ILF genesis, intestinal epithelial cells produce IL-7 that
signals via the IL-7 receptor LTi cells to induce the expression of
lymphotoxin α1β2,34 35 acting on resident lymphoid tissue
Figure 6 Mucosal vascular addressin cell adhesion molecule 1 (MADCAM1) expression in the gut and in the bone marrow of patients with
ankylosing spondylitis (AS). (A and B) Representative images showing MADCAM1 expression in the gut of patients with AS (A) and controls (B).
(C) Quantiﬁcation of MADCAM 1 expression in the gut of patients and controls; *p<0.05. (D–G) Representative images of confocal analysis of
MAdCAM1 and PNAd co-localisation in gut tissues of patients with AS. (D) Single staining for MAdCAM1; (E) single staining for PNAd; (F) nuclei
counterstained with toto-3 (blue). (G) Merged double staining of MAdCAM1 and PNAd. (H and I) Representative images showing
MADCAM1-positive cells in the bone marrow of patients with AS (H) and controls (I). (J) Quantiﬁcation of MADCAM1 in the bone marrow of
patients with AS and controls. (K and N) Representative images of confocal analysis of MAdCAM1 and PNAd co-localisation in bone marrow
biopsies of patients with AS. (K) Single staining for MAdCAM1; (L) single staining for PNAd; (M) nuclei counterstained with toto-3 (blue). (N)
Merged double staining of MAdCAM1 and PNAd. (A and B, D–G and K–N) Original magniﬁcation ×250. (H and I) Original magniﬁcation ×630.
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organiser cells for the organisation of lymphocytes into the
cryptopatches. ILC3 in humans have been developmentally
related to LTi cells, and this process seems to be also dependent
on the IL-7 signalling.11 12 Although cryptopatches have been
extensively demonstrated in murine intestine, in humans their
presence has been proved only in colon,36 being lacking a
deﬁnitive demonstration of their presence in small intestine. In
this study, we, however, provide the ﬁrst demonstration of the
presence of aggregates of LTi in the small intestine of patients
with AS but not in controls, in close proximity to intestinal
crypts, these structures being highly suggestive for crypto-
patches. The absence of cryptopatches in normal ileal samples
we observed could suggest that, in physiological conditions,
they may exist only during a small window of time just after
birth or, alternatively, that they need bacterial stimulation to
develop. Postnatal development of cryptopatches, in fact, seems
to be dependent by the presence of bacteria and ileal dysbiosis
has been recently proved in AS.37 Cryptopatches have been
hypothesised to be sites of active extrathymic T cell develop-
ment.38–40 In this regard, we also demonstrated that specialised
epithelial cells in the gut of AS, PC, do express IL-7 and that
co-culture of LTi with epithelial cells isolated from patients with
AS strongly induces the differentiation of ILC3, also increasing
the expression of IL-17 and IL-22. Our results might suggest a
pivotal role of these specialised epithelial cells in activating and
amplifying intestinal innate immune responses in the gut of
patients with AS resulting in active ILC3 differentiation.
An intriguing theory linking gut and joint inﬂammation con-
cerns the aberrant trafﬁcking of gut-derived T cells.41 Recently,
an entheseal subset of T cells, highly responsive to IL-23, has
been described in a murine model of spondyloarthritis.5
Although the intestinal presence of these cells was not studied
in the paper by Sherlock,5 several immunological similarities are
shared between the murine entheseal T cells and ILC3 we
described in our study. Both murine and humans cells were in
fact Lyn negative, do express the IL-23R and produce IL-17 and
IL-22. ILC3 were also characterised by a strong expression of
the integrin α4β7 that has been demonstrated to regulate
the homing of intestinal T cells.42 Interestingly, MAdCAM1, the
counter-receptor of α4β7,43 was signiﬁcantly upregulated in the
HEVs of the gut and the BM of patients with AS, suggesting a
role for this receptor in chemoattracting ILC3 at the site of
active AS inﬂammation.
A strong correlation has been recently demonstrated between
the presence of gut inﬂammation and the degree of spinal
inﬂammation in AS.44 In this regard, our study indicates that a
gut–joint/spine axis exists in AS where ILC3 actively differenti-
ate in the gut and migrate in extraintestinal sites where, through
the production of IL-17 and IL-22, they may be responsible for
the induction of inﬂammation. Data on the effect of anti-TNF
treatment on circulating and gut ILC3 and of MADCAM1
expression in the gut point towards a more complex anti-
inﬂammatory pathway of this class of drugs.
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